CHS 1000
Alternative Names: CHS-1000Latest Information Update: 19 Aug 2024
Price :
$50 *
At a glance
- Originator Coherus BioSciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; LILRB2 protein inhibitors; Macrophage stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours